|
JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
１，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
|
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
|
US5266573A
(en)
|
1989-08-07 |
1993-11-30 |
Elf Sanofi |
Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
US5763263A
(en)
|
1995-11-27 |
1998-06-09 |
Dehlinger; Peter J. |
Method and apparatus for producing position addressable combinatorial libraries
|
|
JP3370340B2
(ja)
|
1996-04-12 |
2003-01-27 |
ワーナー―ランバート・コンパニー |
チロシンキナーゼの不可逆的阻害剤
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
BRPI0017548B8
(pt)
|
1999-02-10 |
2023-05-02 |
Astrazeneca Ab |
Composto
|
|
YU90901A
(sh)
|
1999-06-21 |
2004-07-15 |
Boehringer Ingelheim Pharma Gmbh. & Co.Kg. |
Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
CA2403152C
(en)
|
2000-04-08 |
2008-10-28 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
DE10042061A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
EP1415987B1
(en)
|
2000-10-20 |
2007-02-28 |
Eisai R&D Management Co., Ltd. |
Nitrogenous aromatic ring compounds as anti cancer agents
|
|
DE10063435A1
(de)
|
2000-12-20 |
2002-07-04 |
Boehringer Ingelheim Pharma |
Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
WO2002066445A1
(en)
*
|
2001-02-21 |
2002-08-29 |
Mitsubishi Pharma Corporation |
Quinazoline derivatives
|
|
EP1249451B1
(en)
|
2001-04-13 |
2006-06-21 |
Pfizer Products Inc. |
Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
|
|
BR0214606A
(pt)
|
2001-11-30 |
2004-09-14 |
Pfizer Prod Inc |
Processos para a preparação de derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
|
|
BR0307544A
(pt)
|
2002-02-01 |
2004-12-07 |
Ariad Gene Therapeutics Inc |
Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
|
|
JP4201716B2
(ja)
|
2002-03-05 |
2008-12-24 |
メルク フロスト カナダ リミテツド |
カテプシンシステインプロテアーゼ阻害剤
|
|
DE10217689A1
(de)
*
|
2002-04-19 |
2003-11-13 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
PE20040945A1
(es)
|
2003-02-05 |
2004-12-14 |
Warner Lambert Co |
Preparacion de quinazolinas substituidas
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
US20070032513A1
(en)
|
2003-09-16 |
2007-02-08 |
Hennequin Laurent F A |
Quinazoline derivatives
|
|
AP2204A
(en)
*
|
2004-05-06 |
2011-02-07 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides.
|
|
EP1792898A1
(en)
*
|
2004-09-01 |
2007-06-06 |
Mitsubishi Pharma Corporation |
Molecular chaperone function regulator
|
|
KR20200019263A
(ko)
|
2004-09-02 |
2020-02-21 |
제넨테크, 인크. |
헤지호그 신호전달에 대한 피리딜 억제제
|
|
CN108421044A
(zh)
|
2005-02-03 |
2018-08-21 |
综合医院公司 |
治疗吉非替尼耐药性癌症的方法
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
WO2007055513A1
(en)
|
2005-11-08 |
2007-05-18 |
Hanmi Pharm. Co., Ltd. |
Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof
|
|
KR100832594B1
(ko)
|
2005-11-08 |
2008-05-27 |
한미약품 주식회사 |
다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
|
|
KR20080015594A
(ko)
|
2006-08-16 |
2008-02-20 |
주식회사종근당 |
포스포디에스테라제 저해제로서 유용한 퀴나졸린 유도체 및그 제조방법
|
|
US8604044B2
(en)
|
2006-09-11 |
2013-12-10 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
TWI377944B
(en)
|
2007-06-05 |
2012-12-01 |
Hanmi Holdings Co Ltd |
Novel amide derivative for inhibiting the growth of cancer cells
|
|
US20090209536A1
(en)
|
2007-06-17 |
2009-08-20 |
Kalypsys, Inc. |
Aminoquinazoline cannabinoid receptor modulators for treatment of disease
|
|
AU2008298948B2
(en)
|
2007-09-12 |
2014-09-04 |
F. Hoffmann-La Roche Ag |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
EP2214675B1
(en)
|
2007-10-25 |
2013-11-20 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
EP2331530B8
(en)
|
2008-09-26 |
2013-12-25 |
National Health Research Institutes |
Fused multicyclic compounds as protein kinase inhibitors
|
|
JP5721709B2
(ja)
|
2009-07-02 |
2015-05-20 |
ニューゲン セラピューティクス， インコーポレイテッド |
リンを含むキナゾリン化合物および使用方法
|
|
CN105037333A
(zh)
|
2009-12-21 |
2015-11-11 |
张强 |
新的喹唑啉衍生物
|
|
CN102382065B
(zh)
|
2010-08-30 |
2014-05-28 |
山东轩竹医药科技有限公司 |
苯胺取代的喹唑啉衍生物
|
|
CN102382106A
(zh)
|
2010-08-30 |
2012-03-21 |
黄振华 |
苯胺取代的喹唑啉衍生物
|
|
CN102452989B
(zh)
|
2010-10-19 |
2014-10-22 |
山东轩竹医药科技有限公司 |
苯胺取代的喹唑啉衍生物
|
|
KR102061743B1
(ko)
*
|
2011-03-04 |
2020-01-03 |
뉴젠 세러퓨틱스 인코포레이티드 |
알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
|
|
CN102731485B
(zh)
|
2011-04-02 |
2016-06-15 |
齐鲁制药有限公司 |
4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
|
|
CN102918029B
(zh)
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
EP3925962A1
(en)
|
2011-05-31 |
2021-12-22 |
Rakovina Therapeutics Inc. |
Tricyclic inhibitors of poly(adp-ribose) polymerase
|
|
KR20140051944A
(ko)
*
|
2011-07-13 |
2014-05-02 |
노파르티스 아게 |
탄키라제 억제제로서 사용하기 위한 4-피페리디닐 화합물
|
|
CN102898386B
(zh)
|
2011-07-27 |
2015-07-29 |
上海医药集团股份有限公司 |
喹唑啉衍生物、其制备方法、中间体、组合物及其应用
|
|
CN102516232A
(zh)
|
2011-12-14 |
2012-06-27 |
无锡美克赛医药科技有限公司 |
一种ErbB2的小分子选择性抑制剂及其应用
|
|
CN103987700B
(zh)
|
2012-03-09 |
2016-08-31 |
江苏豪森药业集团有限公司 |
4-喹唑啉胺类衍生物及其用途
|
|
US9550738B2
(en)
|
2012-05-14 |
2017-01-24 |
Hangzhouderenyucheng Biotechnology Ltd |
Bicyclic compounds as kinases inhibitors
|
|
LT3495367T
(lt)
*
|
2012-06-13 |
2021-02-25 |
Incyte Holdings Corporation |
Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
|
|
CN102942561A
(zh)
|
2012-11-06 |
2013-02-27 |
深圳海王药业有限公司 |
4-氨基喹唑啉杂环化合物及其用途
|
|
CN103965120B
(zh)
|
2013-01-25 |
2016-08-17 |
上海医药集团股份有限公司 |
喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
|
|
TWI609012B
(zh)
|
2013-04-28 |
2017-12-21 |
廣東東陽光藥業有限公司 |
氨基喹唑啉類衍生物及其鹽和使用方法
|
|
CN104513229A
(zh)
|
2013-09-28 |
2015-04-15 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物及其制备方法
|
|
JP6559123B2
(ja)
|
2013-10-10 |
2019-08-14 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓｇ１２ｃの阻害剤
|
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
|
US10196365B2
(en)
|
2014-08-15 |
2019-02-05 |
Arromax Pharmatech Co., Ltd. |
Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
|
|
WO2016055982A1
(en)
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
|
FI3236943T3
(fi)
|
2014-12-24 |
2023-04-27 |
Principia Biopharma Inc |
Koostumuksia ileo-jejunaaliseen lääkkeenantoon
|
|
US10287266B2
(en)
|
2015-06-19 |
2019-05-14 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
|
US9890187B2
(en)
|
2015-06-26 |
2018-02-13 |
Epos-Iasis Research And Development, Ltd. |
Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
|
|
GB201517216D0
(en)
*
|
2015-09-29 |
2015-11-11 |
Cancer Res Technology Ltd And Astex Therapeutics Ltd |
Pharmaceutical compounds
|
|
JP7114076B2
(ja)
|
2015-12-22 |
2022-08-08 |
シャイ・セラピューティクス・エルエルシー |
がん及び炎症性疾患の処置のための化合物
|
|
CN105348271A
(zh)
|
2015-12-23 |
2016-02-24 |
常州润诺生物科技有限公司 |
喹唑啉类衍生物药用用途及其制备方法
|
|
JP2022502496A
(ja)
|
2018-09-25 |
2022-01-11 |
ブラック ダイアモンド セラピューティクス，インコーポレイティド |
チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
|
|
KR20210137422A
(ko)
|
2018-09-25 |
2021-11-17 |
블랙 다이아몬드 테라퓨틱스, 인코포레이티드 |
티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도
|
|
CN109265449B
(zh)
|
2018-11-07 |
2021-11-23 |
沈阳工业大学 |
Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
|
|
WO2020139748A1
(en)
|
2018-12-28 |
2020-07-02 |
Cedars-Sinai Medical Center |
Methods of treating inflammatory bowel diseases that target ripk2
|
|
CN119390683A
(zh)
|
2019-08-15 |
2025-02-07 |
黑钻治疗公司 |
炔基喹唑啉化合物
|
|
EP4097083A1
(en)
|
2020-01-29 |
2022-12-07 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and methods of using same
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
US11608343B2
(en)
|
2020-04-24 |
2023-03-21 |
Boehringer Ingelheim International Gmbh |
Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
|
|
WO2022040377A1
(en)
|
2020-08-20 |
2022-02-24 |
Black Diamond Therapeutics, Inc. |
Methods for preparing quinazoline derivatives
|
|
WO2022076671A1
(en)
|
2020-10-08 |
2022-04-14 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers using quinazoline derivatives
|
|
TWI910256B
(zh)
|
2020-11-02 |
2026-01-01 |
美商黑鑽醫療公司 |
使用經炔取代之喹唑啉衍生物類以治療癌症之方法
|
|
IL311354A
(en)
|
2021-09-21 |
2024-05-01 |
Black Diamond Therapeutics Inc |
polymorphs as ERBB inhibitors
|
|
WO2025038731A1
(en)
|
2023-08-15 |
2025-02-20 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers with alkyne substituted quinazoline derivatives
|